- Home
- MGTX
as 07-26-2024 4:00pm EST
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 327.3M | IPO Year: | N/A |
| Target Price: | $26.00 | AVG Volume (30 days): | 212.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.17 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.49 - $7.60 | Next Earning Date: | 08-08-2024 |
| Revenue: | $697,000 | Revenue Growth: | -79.09% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 447.29% |
Latest MeiraGTx Holdings plc News
MGTX Breaking Stock News: Dive into MGTX Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
MeiraGTx Holdings (NASDAQ:MGTX) investors are sitting on a loss of 86% if they invested five years ago
Simply Wall St.
2 months ago
Here's Why It's Unlikely That MeiraGTx Holdings plc's (NASDAQ:MGTX) CEO Will See A Pay Rise This Year
Medical Device Network
2 months ago
Ireland – the jewel in the life sciences crown?
Simply Wall St.
2 months ago
Analyst Forecasts For MeiraGTx Holdings plc (NASDAQ:MGTX) Are Surging Higher
GuruFocus.com
3 months ago
MeiraGTx Holdings PLC Reports First Quarter 2024 Financial Results
Simply Wall St.
3 months ago
MeiraGTx Holdings First Quarter 2024 Earnings: US$0.32 loss per share (vs US$0.62 loss in 1Q 2023)
GlobeNewswire
3 months ago
MeiraGTx Reports First Quarter 2024 Financial and Operational Results
Simply Wall St.
3 months ago
MeiraGTx Holdings plc (NASDAQ:MGTX): Is Breakeven Near?
Compare MGTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MGTX MeiraGTx Holdings plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.